16 results about "Acetaminophen" patented technology

This invention discloses a polyethylene glycol-modified magnesium boride nanosheet and its application in treating acute liver failure and hepatic encephalopathy caused by acetaminophen. The nanosheet uses magnesium boride nanosheets as a core, with polyethylene glycol modified on the surface to improve biocompatibility. The nanosheet of this invention exhibits good antioxidant properties and can be used to prepare nanomedicines for treating acute liver failure and / or hepatic encephalopathy caused by acetaminophen. It generates reducing hydrogen gas through a hydrolysis reaction, effectively scavenging reactive oxygen species at the site of liver failure, thereby inhibiting inflammatory responses and effectively alleviating symptoms caused by acute liver failure.

Disclosed in the present application are a method and drug for preventing or treating a neurodegenerative disease, whereby a therapeutically effective amount of gliclazide or a pharmaceutically acceptable salt thereof or a combination of gliclazide or a pharmaceutically acceptable salt thereof and acetaminophen or a pharmaceutically acceptable salt thereof is used or comprised. The method and drug of the present invention can significantly alleviate symptoms such as hyposmia, cognitive dysfunction, and psychiatric symptoms in patients with neurodegenerative diseases that cannot be treated with existing drugs, and can be particularly used for controlling the progression of neurodegenerative diseases.

The application relates to the technical field of pharmaceutical chemistry, and discloses a flurbiprofen ester enantiomer prodrug compound, a preparation method thereof, a pharmaceutical composition and purposes, the compound is (R)-AF377 or (S)-AF377, is formed by covalently connecting a carboxyl of (R)-flurbiprofen, (S)-flurbiprofen and a phenolic hydroxyl of acetaminophen through an ester bond, corresponding chiral carbons are R configuration and S configuration respectively, and structures are shown in formula (I) and formula (II). The application further provides a preparation method of the compound, a pharmaceutical composition containing the compound and purposes of the compound in pain, inflammation or fever treatment. The compound has high optical purity, releases an active ingredient in the liver, (S)-AF377 has synergistic anti-inflammatory analgesic activity, (R)-AF377 has independent analgesic activity, can reduce side effects of single drug use, improves bioavailability, and provides a new drug selection for treatment of mild to moderate inflammatory pain.

This invention provides a coumarin-chalcone hybrid compound, its preparation method, and its applications. The structure of the coumarin-chalcone hybrid compound is shown in Formula I. The coumarin-chalcone hybrid compound provided by this invention has a simple and easy synthesis process, readily available raw materials, and can significantly activate the transcriptional activity of Nrf2 at both the cellular and animal levels. It exhibits high safety, good cell membrane permeability, and can be taken orally. After oral administration, it primarily results in high exposure in the liver and can effectively alleviate liver damage caused by acetaminophen and alcohol.

This invention discloses an Acinetobacter DL27 strain and its application in the degradation of acetaminophen, belonging to the field of microbial technology. This strain is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 38039, deposited on April 3, 2026, and taxonomically named Acinetobacter. Acinetobacter sp . This invention has screened a strain of Acinetobacter DL27 that can efficiently degrade acetaminophen, and it can efficiently degrade acetaminophen in wastewater from actual sewage treatment plants and agricultural soils, which has important application value in the bioremediation of acetaminophen in complex environments.

1. Name of the product in this design: Packaging Bottle (Acetaminophen). 2. Intended use of this design: for pharmaceutical packaging. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key points: 3D view 1. 5. The design for which protection is sought includes color.

The present disclosure relates to liquid formulations containing acetaminophen and ibuprofen. In particular, the present disclosure relates to liquid formulations comprising acetaminophen, ibuprofen, and a sulfite compound. Such liquid formulations are suitable for parenteral (e.g., intravenous) administration. The present disclosure also relates to terminally-sterilized acetaminophen / ibuprofen liquid formulations. The present disclosure also relates to methods of treating patients by administration of such formulations and polymeric infusion containers, including flexible polymeric infusion containers, containing such formulations.

The application discloses application of SLC2A1 in treatment of paracetamol-induced acute liver injury, and the drug comprises a substance for up-regulating Slc2a1 gene or enhancing SLC2A1 protein level. SLC2A1 expression plays a key role in the disease progression of acute liver injury, and a small molecule compound AS1949490 can increase the level of SLC2A1, thereby promoting the expression of liver macrophage efferocytosis receptors, so as to activate efferocytosis. In addition, AS1949490 can also significantly reduce the increase of ALT and AST contents of the liver caused by paracetamol-induced acute liver injury, and reduce the liver injury area.

This invention provides a high-performance liquid chromatography (HPLC) method for detecting sodium docusate content, relating to the field of pharmaceutical analysis, including sample preparation and detection. Sample preparation involves accurately weighing and grinding acetaminophen / vitamin C effervescent tablets into powder, adding a mixed alcohol-EDTA composite solvent, and ultrasonically dispersing. Then, a bifunctional modified limiting medium, mesoporous silica dispersion, is added, followed by vortexing, centrifugation, and membrane filtration to obtain the test sample. Detection involves performing HPLC on the test sample, using an organic phase and an aqueous phase; wherein the organic phase is acetonitrile, and the aqueous phase is a mixed ionic liquid system. This method is effective for detecting sodium docusate content in compound preparations such as acetaminophen / vitamin C effervescent tablets, and has advantages such as high specificity, simplicity, speed, high sensitivity, accuracy, and reliability.

The present disclosure relates to liquid formulations containing acetaminophen and ibuprofen. In particular, the present disclosure relates to liquid formulations comprising acetaminophen, ibuprofen, and a sulfite compound. Such liquid formulations are suitable for parenteral (e.g., intravenous) administration. The present disclosure also relates to terminally-sterilized acetaminophen / ibuprofen liquid formulations. The present disclosure also relates to methods of treating patients by administration of such formulations and polymeric infusion containers, including flexible polymeric infusion containers, containing such formulations.

The present invention relates to liquid suspensions of acetaminophen. The present invention relates to pharmaceutical liquid suspensions suitable for oral administration. More specifically, the present invention relates to pharmaceutical liquid suspensions containing acetaminophen, wherein the suspension is formulated with acetaminophen particles having a d50 less than or equal to 10 µm and a d90 less than or equal to 35 µm, such that browning discoloration is reduced over the course of long term storage.

The application discloses a kind of pharmaceutical composition for treating liver injury of acetylaminophenol permeation and application, belong to biological medicine field.The composition is composed of N-acetylcysteine or its pharmaceutically acceptable salt, 8-oxo guanine DNA glycosylase 1 specific activator, preferably the activator is TH10785 and its derivative, synergistic effect of both.The composition can break through the traditional 8 hours treatment window of NAC, realize late intervention in poisoning, play the efficacy by repairing DNA oxidative damage, inhibiting Z-DNA generation, blocking ZBP1 path, inhibiting hepatocyte pyroptosis and liver inflammation.Drug can be made into various dosage forms, and matched special treatment kit.The application prolongs clinical treatment time, and double target points synergistically improve treatment effect, target point is novel, applicability is strong, with good clinical transformation prospect.

The application belongs to the technical field of biology, and discloses application of a gallic acid derivative VM in preparation of a product for treating or preventing liver diseases; the gallic acid derivative VM provided by the application has a significant inhibiting effect on accumulation of AST and ALT in alcohol-induced HepG2 cells, has a significant promoting effect on activity of ADH, and has good alcohol-induced liver injury protection activity; in acetylaminophenol (APAP)-induced HepG2 cells, the VM can significantly antagonize a significant decrease in GSH level of endogenous antioxidants in liver cells caused by APAP treatment, effectively maintains or even improves GSH reserves in the cells, indicates that the VM can enhance the antioxidant defense capacity of the cells, and can also significantly inhibit excessive generation of ROS induced by APAP, and has good acetylaminophenol-induced liver injury protection activity.